

Medication Safety in Transitions of Care: Getting it Right
November 5, 2021
VIRTUAL EDUCATIONAL EVENT

This educational activity is jointly provided by:



Target Audience: Physicians, patient safety officers, medication safety officers, pharmacists, nurses, quality/risk professionals

Overview: The Maryland Patient Safety Center's (MPSC) Annual Medication Safety Conference addresses key medication management and safety issues in healthcare. This year the conference will focus on the medication safety issues in transitions for care between facilities. Obtaining the best possible medication history, best practices in medication reconciliation and exploring metrics to measure the quality and effectiveness of the process will be presented.

Learning Objectives:

At the conclusion of this activity, participants should be better able to:

Objectives:

1. Describe the requirements of the medication reconciliation Joint Commission standards
2. Describe best practices to achieve compliance with Joint Commission medication reconciliation requirements
3. Describe the process utilized by two hospitals to obtain the best possible medication history
4. Identify failure points in the medication reconciliation process
5. Name strategies to remediate potential failure points during the medication reconciliation process
6. List current barriers and enablers in Canada to achieving consistent and reliable MedRec processes at all transitions in healthcare delivery.
7. Identify metrics utilized in Canada to evaluate the quality of the Medication Reconciliation process in transitions of care
8. List the top 10 most important medication safety issues reported to ISMP during the past 12 months
9. Review results from the 2021 ISMP Perioperative Medication Safety Self-Assessment to learn about the most common weaknesses and what to do about them
10. Discuss strategies that can be employed to help reduce the potential for serious medication errors during 2022

Faculty:

Opening Keynote: *Robert Campbell, PharmD, BCSCP*, currently serves as the Clinical Director, Standards Interpretation Group at The Joint Commission. Dr. Campbell is responsible for providing interpretation of Joint Commission standards in all accreditation programs, with

special emphasis on standards issues. Dr. Campbell also serves as the Director of Medication Management for the Joint Commission Enterprise. In this role, he functions as the subject matter expert for medication management related topics; assists with interpreting the intent of standards, as well as the development and revision of standards; provides guidance to organizations and Surveyors; and supports the accreditation and certification process across the Joint Commission Enterprise. Dr. Campbell also continues to function as a Surveyor for The Joint Commission in the Hospital Accreditation and Critical Access Hospital Accreditation Programs, as well as a Reviewer in the Medication Compounding Certification Program to assess compliance with accreditation and certification program standards. He is a member of the Accreditation Council for the Joint Commission and a member of the National Coordinating Council for Medication Error Reporting and Prevention.

- **Featured Speakers:**

Robert Campbell, Pharm D

Sandip Sheth, PharmD

Margaret Curtin, PharmD

Daryn Norwood, PharmD

Ifeanyi Egbunike-Chukwuma, Pharm.D

Carolyn Hoffman, RN, BSN, MN

Michael Cohen, RPh, MS, ScD (hon.), DPS (hon.), FASHP

Agenda

8:00am to 8:15am

Welcome and Overview

Blair Eig, MD; President and CEO, MPSC

8:15am to 9:15 am

Opening Keynote - Joint Commission Medication Reconciliation Requirements

Robert Campbell, PharmD.; Director, Clinical Standards Interpretation and Director, Medication Management - Joint Commission Enterprise

9:15am to 10:15am

From Med Wreck to Med Rec: Obtaining the best possible medication history

Margaret Curtin, PharmD; Clinical Pharmacy Manager/Residency Program Director; Howard County General Hospital

Daryn Norwood, PharmD; Director Pharmacy Services, Howard County General Hospital

Ifeanyi Egbunike-Chukwuma, PharmD; Director of Pharmacy, University of Maryland Medical Center Midtown Campus

10:15am to 10:30am

BREAK

10:30a to 11:30am

Best Practices in Medication Reconciliation

Sandip Sheth, PharmD; Consultant, Sheth Clinical Consulting

11:30a to 12:15pm

LUNCH

12:15pm to 1:15pm

Reflections from Canada on Leading MedRec Practices

Carolyn Hoffman RN; CEO Institute for Safe Medication Practices- Canada

1:15pm to 2:15pm

An ISMP update on medication safety issues during 2021-

Michael Cohen PharmD., President, Institute for Safe Medication Practices

2:15pm to 2:30PM

Summary, closing, evaluation

Blair Eig, MD, President and CEO, MPSC

ACCREDITED CONTINUING EDUCATION

Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Maryland Patient Safety Center. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 5.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians

AXIS Medical Education designates this live activity for a maximum of 5.0 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists

This application-based activity is approved for 5.0 contact hours of continuing pharmacy education credit JA4008106-9999-21-095-L05-P.

Credit Designation for Nursing

AXIS Medical Education designates this continuing nursing education activity for 5.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Quality Professionals

This program has been approved by the National Association for Healthcare Quality for a maximum of 5.0 CPHQ continuing education credits for this event.

Risk Management

This meeting has been approved for a total of 5.0 contact hours of Continuing Education Credit toward fulfillment of the requirements of ASHRM designations of FASHRM (Fellow) and DFASHRM (Distinguished Fellow) and towards CPHRM renewal.

AXIS Contact Information

For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The **faculty** reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

Name of Faculty or Presenter	Reported Financial Relationship
Robert Campbell, PharmD	Nothing to disclose
Margaret Curtin, PharmD	Nothing to disclose
Daryn Norwood, PharmD	Nothing to disclose
Ifeanyi Egbunike-Chukwuma, PharmD	Nothing to disclose
Sandip Sheth, PharmD	Nothing to disclose
Carolyn Hoffman, RN, BSN, MN	Nothing to disclose
Michael Cohen, RPh	Nothing to disclose

The following **directors, planners, managers and reviewers** reported no financial relationships they have with any ineligible company of any amount during the past 24 months:

Name of Planner/Manager/Reviewer	Reported Financial Relationship
Maryam D’Alberto, PharmD	Nothing to disclose
Bonnie DiPietro, RN, MS	Nothing to disclose
Ifeayani Egbunike-Chukwuma, PharmD	Nothing to disclose
Blair Eig, MD, MBA, MA	Nothing to disclose
E. Robert Feroli, PharmD	Nothing to disclose
Alyssa Grieshaber, RN, BSN	Nothing to disclose
Cheri Hahn, RN, MS	Nothing to disclose
Jacqueline Hartford, PharmD	Nothing to disclose
Jeanine Jackson, PharmD, MD, MA	Nothing to disclose
Vaishali Khushalani, PharmD	Nothing to disclose
Dee Morgillo, MEd., MT(ASCP), CHCP	Nothing to disclose
Anna Oberste, PharmD, MPH	Nothing to disclose
Glorimar Rivera Quinones, PharmD	Nothing to disclose
Susan Shermock, PharmD	Nothing to disclose
Emil N. Sidawy, PharmD	Nothing to disclose
Ronald Viggiani, MD	Nothing to disclose

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Requirements for credit:

- Attend/participate in the educational activity and review all course materials.
- Complete the CE Declaration form online by **11:59 pm ET December 7, 2021**. Instructions will be provided. If you do not enter the online portal by the above date, you will not be able to retrieve your statement of participation.
- Upon successful completion of the online form, your statement of completion will be presented to you to print. For pharmacists, your record will be automatically uploaded to CPE Monitor.